LSBio
IHC-plus™ LXR Alpha+Beta Antibody (aa50-150)

Anti-LXR Alpha/Beta antibody IHC of human skeletal muscle. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody concentration 5 ug/ml. This image was taken for the unconjugated form of this product. Other forms have not been tested.

IHC-plus™ LXR Alpha+Beta Antibody (aa50-150)

Primary AntibodyLSBio Guarantee
Antibody:Rabbit Polyclonal
Applications:Immunohistochemistry (general), Immunohistochemistry, Paraffin, Western Blot
Reactivity:Human
Format:Liquid
See all LXR Alpha+Beta antibodies →
$383.00each
Catalog Number: LS-B262-0.1

For bulk orders or custom formulations:

Request a Quote

Overview

Description
LXR Alpha+Beta antibody LS-B262 is an unconjugated rabbit polyclonal antibody to human LXR Alpha+Beta (aa50-150). Validated for IHC and WB. Tested on 20 paraffin-embedded human tissues. Cited in 1 publication.
Application
IHC, IHC-P, WB
Reactivity
Hu
Predicted Reactivity
Chicken, Mouse, Rat
Intended Use
Research Use Only
Guarantees
This product carries the LSBio 100% Guarantee.
Category
Antibodies > Primary Antibodies > Polyclonal Antibodies
Alternative Names
LXR beta/NR1H2
Recommended Dilution: IHC-P
5 µg/ml
Recommended Dilution: WB
0.5 - 2 µg/ml

Target

Target
LXR Alpha+Beta
Antigen Species
Human
Specificity
LXR alpha and beta isoforms.
Epitope
LXR alpha and beta isoforms.

Antibody

Host Species
Rabbit
Clonality
Polyclonal

Immunogen

Immunogen
A synthetic peptide made to an internal portion of the human LXR protein sequence (between residues 50-150). Percent identity by BLAST analysis: Rat, Mouse (92%); Chicken (90%).
Immunogen Type
Synthetic Peptide (Linear)

Format

Conjugate/Label
Unconjugated
Format
Liquid
Formulation
Tris-Glycine, 150 mM NaCl, 0.05% Sodium Azide
Concentration
1.04 mg/mL
Volume
0.1 Milliliter
Animal Free
No
Carrier-Free
Yes
Preservative
Yes
Purification Method
Affinity Purified

Storage & Handling

Storage Conditions
Store at 4°C. Do not freeze.
Recommended Storage Buffer
Tris-Glycine, 150 mM NaCl
Cytoplasmic LXR expression is an independent marker of poor prognosis for patients with early stage primary breast cancer. Wanting Shao , Christina Kuhn, Doris Mayr, Nina Ditsch, Magdalena Kailuwait, Verena Wolf, Nadia Harbeck, Sven Mahner, Udo Jeschke , Vincent Cavaillès, Sophie Sixou. Journal of cancer research and clinical oncology. 2021 Sep;;147:2535-2544. PubMed: 34085098 PMC: PMC8310839

Request SDS/MSDS

To request an SDS/MSDS form for this product, please contact our Technical Support department at: technical@vectorlabs.com.